These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 22869678

  • 61. Intravenous immunoglobulin for the treatment of Kawasaki disease in children.
    Oates-Whitehead RM, Baumer JH, Haines L, Love S, Maconochie IK, Gupta A, Roman K, Dua JS, Flynn I.
    Cochrane Database Syst Rev; 2003; 2003(4):CD004000. PubMed ID: 14584002
    [Abstract] [Full Text] [Related]

  • 62. Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study.
    Nanishi E, Nishio H, Takada H, Yamamura K, Fukazawa M, Furuno K, Mizuno Y, Saigo K, Kadoya R, Ohbuchi N, Onoe Y, Yamashita H, Nakayama H, Hara T, Ohno T, Takahashi Y, Hatae K, Harada T, Shimose T, Kishimoto J, Ohga S, Hara T.
    J Am Heart Assoc; 2017 Jul 06; 6(7):. PubMed ID: 28684643
    [Abstract] [Full Text] [Related]

  • 63. N-terminal pro-brain natriuretic peptide and risk of coronary artery lesions and resistance to intravenous immunoglobulin in Kawasaki disease.
    Yoshimura K, Kimata T, Mine K, Uchiyama T, Tsuji S, Kaneko K.
    J Pediatr; 2013 Jun 06; 162(6):1205-9. PubMed ID: 23290510
    [Abstract] [Full Text] [Related]

  • 64. Role of glucocorticoids in Kawasaki disease.
    Miura M.
    Int J Rheum Dis; 2018 Jan 06; 21(1):70-75. PubMed ID: 29105310
    [Abstract] [Full Text] [Related]

  • 65. Clinical score and transcript abundance patterns identify Kawasaki disease patients who may benefit from addition of methylprednisolone.
    Ogata S, Ogihara Y, Nomoto K, Akiyama K, Nakahata Y, Sato K, Minoura K, Kokubo K, Kobayashi H, Ishii M.
    Pediatr Res; 2009 Nov 06; 66(5):577-84. PubMed ID: 19680167
    [Abstract] [Full Text] [Related]

  • 66. The effects of glucocorticoid plus intravenous immunoglobulin (IVIG) vs IVIG alone on platelet activation in children with Kawasaki disease.
    Wang QQ, Zheng LY, Zhao S.
    Turk J Pediatr; 2023 Nov 06; 65(4):640-649. PubMed ID: 37661679
    [Abstract] [Full Text] [Related]

  • 67. Predictors of intravenous immunoglobulin-resistant Kawasaki disease in children: a meta-analysis of 4442 cases.
    Li X, Chen Y, Tang Y, Ding Y, Xu Q, Sun L, Qian W, Qian G, Qin L, Lv H.
    Eur J Pediatr; 2018 Aug 06; 177(8):1279-1292. PubMed ID: 29948255
    [Abstract] [Full Text] [Related]

  • 68. Acute and late coronary outcomes in 1073 patients with Kawasaki disease with and without intravenous γ-immunoglobulin therapy.
    Lin MT, Sun LC, Wu ET, Wang JK, Lue HC, Wu MH.
    Arch Dis Child; 2015 Jun 06; 100(6):542-7. PubMed ID: 25564534
    [Abstract] [Full Text] [Related]

  • 69. Association between intravenous immunoglobulin dose and outcomes in patients with acute Kawasaki disease.
    Michihata N, Suzuki T, Yoshikawa T, Saito K, Matsui H, Fushimi K, Yasunaga H.
    Eur J Pediatr; 2022 Oct 06; 181(10):3607-3615. PubMed ID: 35925450
    [Abstract] [Full Text] [Related]

  • 70. Initial intravenous gamma-globulin treatment failure in Iranian children with Kawasaki disease.
    Kashef S, Safari M, Amin R.
    Kaohsiung J Med Sci; 2005 Sep 06; 21(9):401-4. PubMed ID: 16248123
    [Abstract] [Full Text] [Related]

  • 71. Role of the Egami Score in Predicting Intravenous Immunoglobulin Resistance in Kawasaki Disease Among Different Ethnicities.
    Loomba RS, Raskin A, Gudausky TM, Kirkpatrick E.
    Am J Ther; 2016 Sep 06; 23(6):e1293-e1299. PubMed ID: 25611359
    [Abstract] [Full Text] [Related]

  • 72. Clinical outcomes of initial dexamethasone treatment combined with a single high dose of intravenous immunoglobulin for primary treatment of Kawasaki disease.
    Lim YJ, Jung JW.
    Yonsei Med J; 2014 Sep 06; 55(5):1260-6. PubMed ID: 25048483
    [Abstract] [Full Text] [Related]

  • 73. Characteristics of Kawasaki disease in older children.
    Cai Z, Zuo R, Liu Y.
    Clin Pediatr (Phila); 2011 Oct 06; 50(10):952-6. PubMed ID: 21628347
    [Abstract] [Full Text] [Related]

  • 74. Fine specificities of natural regulatory T cells after IVIG therapy in patients with Kawasaki disease.
    Burns JC, Touma R, Song Y, Padilla RL, Tremoulet AH, Sidney J, Sette A, Franco A.
    Autoimmunity; 2015 May 06; 48(3):181-8. PubMed ID: 25822882
    [Abstract] [Full Text] [Related]

  • 75. Response of refractory Kawasaki disease to intravenous methylprednisolone.
    Shah I, Prabhu SS.
    Ann Trop Paediatr; 2009 Mar 06; 29(1):51-3. PubMed ID: 19222935
    [Abstract] [Full Text] [Related]

  • 76. Efficacy of intravenous immune globulin therapy combined with dexamethasone for the initial treatment of acute Kawasaki disease.
    Jibiki T, Terai M, Kurosaki T, Nakajima H, Suzuki K, Inomata H, Terashima I, Honda T, Yasukawa K, Hamada H, Kohno Y.
    Eur J Pediatr; 2004 Apr 06; 163(4-5):229-33. PubMed ID: 14963702
    [Abstract] [Full Text] [Related]

  • 77. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China.
    Yang Y, Xu J, Li F, Zhu X.
    Int J Dermatol; 2009 Oct 06; 48(10):1122-8. PubMed ID: 19775409
    [Abstract] [Full Text] [Related]

  • 78. Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease.
    Chan H, Chi H, You H, Wang M, Zhang G, Yang H, Li Q.
    BMC Pediatr; 2019 May 17; 19(1):158. PubMed ID: 31101091
    [Abstract] [Full Text] [Related]

  • 79. Ulinastatin, a urinary trypsin inhibitor, for the initial treatment of patients with Kawasaki disease: a retrospective study.
    Kanai T, Ishiwata T, Kobayashi T, Sato H, Takizawa M, Kawamura Y, Tsujimoto H, Nakatani K, Ishibashi N, Nishiyama M, Hatai Y, Asano Y, Kobayashi T, Takeshita S, Nonoyama S.
    Circulation; 2011 Dec 20; 124(25):2822-8. PubMed ID: 22104548
    [Abstract] [Full Text] [Related]

  • 80. Corticosteroids Added to Initial Intravenous Immunoglobulin Treatment for the Prevention of Coronary Artery Abnormalities in High-Risk Patients With Kawasaki Disease.
    Ae R, Abrams JY, Maddox RA, Schonberger LB, Nakamura Y, Kuwabara M, Makino N, Matsubara Y, Kosami K, Sasahara T, Belay ED.
    J Am Heart Assoc; 2020 Sep 20; 9(17):e015308. PubMed ID: 32811256
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.